Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Neonatology

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 42 articles: HTML format

Single Articles

May 2023
1. BEHR J
   The art of clinical trial design in pulmonary fibrosis.
   Eur Respir J. 2023;61:2300346.
   PubMed    
   
   
   April 2023
2. BRUSCIA EM
   The effects of elexafactor/tezafactor/ivacaftor beyond the epithelium: spurring macrophages to fight infections.
   Eur Respir J. 2023;61:2300216.
   PubMed    
   
   
   
3. CAVINATO L, Luly FR, Pastore V, Chiappetta D, et al
   Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.
   Eur Respir J. 2023;61:2200725.
   PubMed     Abstract available
   
   
   
4. ZHANG S, Shrestha CL, Robledo-Avila F, Jaganathan D, et al
   Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor.
   Eur Respir J. 2023;61:2102861.
   PubMed     Abstract available
   
   
   
5. VAN TONDER AJ, Ellis HC, Churchward CP, Kumar K, et al
   M ycobacterium avium complex genomics and transmission in a London hospital.
   Eur Respir J. 2023;61:2201237.
   PubMed     Abstract available
   
   
   March 2023
6. PULAKKA A, Risnes K, Metsala J, Alenius S, et al
   Preterm birth and asthma and COPD in adulthood: a nationwide register study from two Nordic countries.
   Eur Respir J. 2023 Mar 29:2201763. doi: 10.1183/13993003.01763-2022.
   PubMed     Abstract available
   
   
   
7. DENHOLM JT
   Children and TB pharmacokinetics: no longer in infancy?
   Eur Respir J. 2023;61:2202003.
   PubMed    
   
   
   
8. ASMUS E, Karle W, Brack MC, Wittig C, et al
   Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients.
   Eur Respir J. 2023;61:2202009.
   PubMed     Abstract available
   
   
   February 2023
9. PEDERSEN ESL, Kuehni CE
   Preventing bronchiolitis among infants with non-pharmaceutical interventions outside pandemics: is it realistic?
   Eur Respir J. 2023;61:2202214.
   PubMed    
   
   
   January 2023
10. DHOTE T, Martin C, Regard L, Pesenti L, et al
    Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis.
    Eur Respir J. 2023;61:2202096.
    PubMed    
    
    
    December 2022
11. RINGSHAUSEN FC, Sauer-Heilborn A, Buttner T, Dittrich AM, et al
    Lung transplantation for end-stage cystic fibrosis before and after the accessibility of elexacaftor/tezacaftor/ivacaftor, Germany, 2012-2021.
    Eur Respir J. 2022 Dec 14:2201402. doi: 10.1183/13993003.01402-2022.
    PubMed    
    
    
    
12. MITROPOULOU G, Brandenberg N, Hoehnel S, Ceroni C, et al
    Rectal organoid-guided CFTR modulator therapy restores lung function in a cystic fibrosis patient with the rare 1677delTA/R334W genotype.
    Eur Respir J. 2022;60:2201341.
    PubMed    
    
    
    November 2022
13. WILLERS CC, Frauchiger BS, Stranzinger E, Bauman G, et al
    Feasibility of unsedated lung MRI in young children with cystic fibrosis.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    September 2022
14. BONADIES L, Papi A, Baraldi E
    Is bronchopulmonary dysplasia in adult age a novel COPD endotype?
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
15. UM-BERGSTROM P, Pourbazargan M, Brundin B, Strom M, et al
    Increased cytotoxic T-cells in the airways of adults with former bronchopulmonary dysplasia.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    August 2022
16. BIRKET SE
    A step forward for an intermediate cystic fibrosis population.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
17. NGUYEN-KHOA T, Hatton A, Drummond D, Aoust L, et al
    Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
18. SAFERALI A, Qiao D, Kim W, Raraigh K, et al
    C FTR variants are associated with chronic bronchitis in smokers.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    
19. MUILWIJK D, de Poel E, van Mourik P, Suen SWF, et al
    Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    July 2022
20. MURPHY VE, Jensen ME, Holliday EG, Giles WB, et al
    Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00298-2022.
    PubMed     Abstract available
    
    
    
21. CHASSAGNON G, Campredon A, Vakalopoulou M, Burgel PR, et al
    Diversity of approaches in artificial intelligence: an opportunity for discoveries in thoracic imaging.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
22. ZHANG B, Zhang S
    Radiomics-derived morphological features predict pulmonary function response during lumacaftor/ivacaftor therapy in patients with cystic fibrosis.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    May 2022
23. RIGAUTS C, Aizawa J, Taylor SL, Rogers GB, et al
    R othia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    March 2022
24. ZANNIN E, Rigotti C, Neumann RP, Dellaca RL, et al
    Oscillatory mechanics at 36 weeks post-menstrual age as markers of lung disease in preterm infants: a cohort study.
    Eur Respir J. 2022 Mar 2. pii: 13993003.03023-2021.
    PubMed    
    
    
    
25. KURZ JM, Ramsey KA, Rodriguez R, Spycher B, et al
    Association of lung clearance index with survival in individuals with cystic fibrosis.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    February 2022
26. YEH HI, Hwang TC
    In vitro assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    
27. HIRANI D, Alvira CM, Danopoulos S, Milla C, et al
    Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    
28. GOSS CH, Fajac I, Jain R, Seibold W, et al
    Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    
29. MORRISON CB, Shaffer KM, Araba KC, Markovetz MR, et al
    Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    December 2021
30. RAITA Y, Perez-Losada M, Freishtat RJ, Hahn A, et al
    Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study.
    Eur Respir J. 2021 Dec 16. pii: 13993003.02293-2021.
    PubMed     Abstract available
    
    
    
31. GURDENIZ G, Ernst M, Rago D, Kim M, et al
    Neonatal metabolome of cesarean section and risk of childhood asthma.
    Eur Respir J. 2021 Dec 9. pii: 13993003.02406-2021.
    PubMed     Abstract available
    
    
    
32. KRUIZINGA MD, Essers E, Stuurman FE, Yavuz Y, et al
    Clinical validation of digital biomarkers for pediatric patients with asthma and cystic fibrosis - Potential for clinical trials and clinical care.
    Eur Respir J. 2021 Dec 9. pii: 13993003.00208-2021.
    PubMed     Abstract available
    
    
    
33. REEVES SR
    Primary nasal epithelial cells from patients with cystic fibrosis hold promise for guiding precision medicine and expanding treatment.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
34. SETTE G, Lo Cicero S, Blacona G, Pierandrei S, et al
    Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    November 2021
35. BINGLE CD, Bingle L
    SPLUNC1 comes of age? Predicting acute exacerbations in cystic fibrosis.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
36. KHANAL S, Webster M, Niu N, Zielonka J, et al
    SPLUNC1: a novel marker of cystic fibrosis exacerbations.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    October 2021
37. SATRELL E, Clemm H, Roksund O, Hufthammer KO, et al
    Development of lung diffusion to adulthood following extremely preterm birth.
    Eur Respir J. 2021 Oct 8. pii: 13993003.04103-2020.
    PubMed     Abstract available
    
    
    September 2021
38. HART K, Cousins M, Watkins WJ, Kotecha SJ, et al
    Association of Early Life Factors with Prematurity-Associated Lung Disease: Prospective Cohort Study.
    Eur Respir J. 2021 Sep 29. pii: 13993003.01766-2021.
    PubMed     Abstract available
    
    
    
39. MARTIN C, Burgel PR
    Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
40. MCKONE EF, Ariti C, Jackson A, Zolin A, et al
    Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    July 2021
41. WECKMANN M, Bahmer T, Bulow Sand JM, Rank Ronnow S, et al
    COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy.
    Eur Respir J. 2021 Jul 29. pii: 13993003.03969-2020.
    PubMed     Abstract available
    
    
    June 2021
42. CORIATI A, Sykes J, Lemonnier L, Ma X, et al
    The impact of the high emergency lung transplantation program in cystic fibrosis in France: insight from a comparison with Canada.
    Eur Respir J. 2021 Jun 17. pii: 13993003.00014-2021.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neonatology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: